This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Disruption of protein-protein interactions using pyrrolopyrimidine based α -helix peptide mimetics	<p>Pyrrolopyrimidine-based α-helix peptide mimetics could provide a scaffold for developing small molecule inhibitors of protein-protein interactions. A screen of 900 pyrrolopyrimidine-derived compounds identified two leads that inhibited tumor protein p53 (TP53; p53) protein-protein interactions at submicromolar concentrations. In human lung cancer cells, the compounds increased p53 levels and proapoptotic caspase activity compared with an inactive control compound. Next steps include screening a larger library of pyrrolopyrimidine-based compounds to identify inhibitors of additional protein-protein interactions.</p> <p>SciBX 4(3); doi:10.1038/scibx.2011.88 Published online Jan. 20, 2011</p>	Patent application filed; licensing status undisclosed	<p>Lee, J.H. <i>et. al. J. Am. Chem. Soc.</i>; published online Dec. 20, 2010; doi:10.1021/ja108230s Contact: Hyun-Suk Lim, Indiana University School of Medicine, Indianapolis, Ind. e-mail: limhyun@iupui.edu Contact: Hua Lu, same affiliation as above e-mail: hualu@iupui.edu</p>